New non-invasive glucose monitoring device could transform lives of people with diabetes

NewsGuard 100/100 Score

A new laser sensor that monitors blood glucose levels without penetrating the skin could transform the lives of millions of people living with diabetes.

Currently, many people with diabetes need to measure their blood glucose levels by pricking their fingers, squeezing drops of blood onto test strips, and processing the results with portable glucometers. The process can be uncomfortable, messy and often has to be repeated several times every day.

The new technology, developed by Professor Gin Jose and a team at the University of Leeds, uses a small device with low-powered lasers to measure blood glucose levels without penetrating the skin. It could give people a simpler, pain-free alternative to finger pricking.

The technology has continuous monitoring capabilities making it ideal for development as a wearable device. This could help improve the lives of millions of people by enabling them to constantly monitor their glucose levels without the need for an implant.

It is also good news for healthcare providers as it could provide a simpler and cheaper alternative to both of the current methods - finger pricking, which uses disposable sample strips, or invasive continuous monitors, which use implanted sensors that need regular replacement.

Professor Jose said: "Unlike the traditional method, this new non-invasive technology can constantly monitor blood glucose levels.

"As well as being a replacement for finger-prick testing, this technology opens up the potential for people with diabetes to receive continuous readings, meaning they are instantly alerted when intervention is needed. This will allow people to self-regulate and minimise emergency hospital treatment. This wearable device would then be just one step from a product which sends alerts to smart phones or readings directly to doctors, allowing them to profile how a person is managing their diabetes over time."

The technology is licensed to Glucosense Diagnostics, a spin-out company jointly formed and funded by the University of Leeds and NetScientific plc, a biomedical and healthcare technology group specialising in commercialising transformative technologies from leading universities and research institutes.

Sir Richard Sykes, Chairman of NetScientific, said: "Diabetes is a growing problem, with the need for non-invasive glucose monitoring becoming ever more critical. This unique technology could help empower millions of people to better manage their diabetes and minimise interventions with healthcare providers. The ultimate development of two distinct products - a finger-touch and a wearable - could give people with different types of diabetes the option of a device that best suits their lifestyle."

At the heart of the new technology is a piece of nano-engineered silica glass with ions that fluoresce in infrared light when a low power laser light hits them. When the glass is in contact with the users' skin, the extent of fluorescence signal varies in relation to the concentration of glucose in their blood. The device measures the length of time the fluorescence lasts for and uses that to calculate the glucose level in a person's bloodstream without the need for a needle. This process takes less than 30 seconds.

Professor Jose said: "The glass used in our sensors is hardwearing, acting in a similar way as that used in smartphones. Because of this, our device is more affordable, with lower running costs than the existing self-monitoring systems.

"Currently, we are piloting a bench top version in our clinical investigations but aim to develop two types of devices for the market. One will be a finger-touch device similar to a computer mouse. The other will be a wearable version for continuous monitoring."

The results of a pilot clinical study, carried out at the Leeds Institute of Cardiovascular and Metabolic Medicine under the supervision of Professor Peter Grant, suggest that the new monitor has the potential to perform as well as conventional technologies. More clinical trials and product optimization are required for regulatory approvals and before the technology can be put on the market.

Professor Grant, Professor of Medicine at the University of Leeds and Consultant diabetes specialist, said: "Non-invasive monitoring will be particularly valuable in young people with Type 1 diabetes. Within this group, those who are attempting very tight control such as young women going through pregnancy or people who are experiencing recurrent hypoglycaemia could find this technology very useful."

Professor Jose's research is based in the Institute for Materials Research in the University of Leeds' School of Chemical and Process Engineering. The initial feasibility study was funded by the NIHR i4i and the research was supported by the Engineering and Physical Sciences Research Council (EPSRC) and the University of Leeds Research and Innovation Services.

Case study:

Donna Ineson, 32, of Horsforth, Leeds, is a quality administrator and has a five-year-old daughter. She was involved in testing the device. She has lived with type 1 diabetes since she was nine.

"Having something as simple as a laser scanner would make my life a lot easier. At the moment, I am supposed to check my blood sugar levels 4 to 6 times a day. I find it quite disruptive to have to stop everything and go through this routine of pricking my finger and taking the measurement. It depends on my mood and how busy I am but, to be honest, often I am only checking myself two times a day. That is a risk with erratic diabetes like mine. I am also supposed to change the needles at every use, but that makes the process longer. The reality of being a mum and working means you often feel you just don't have time.

"I was first told I had diabetes when I was nine. It was painful then because my fingers were much smaller. Even now, if I look at my fingers, I have small marks like blood blisters all over them. They sting if I am doing something slicing fruits."

"We have been stuck with essentially the same technology for so long. We really do need to move forward from this and this new device looks like it is going to do that."


  1. Karl Cammann Karl Cammann Germany says:

    Without presenting the Performance Data according to the relevant ISO norms (a.o. accuracy, Validation, etc.) the presented information is useless. Several hundred Dollars of venture capital has already being wasted during the last decades even by scientifically more convincing approaches.

    • Alec Renwick Alec Renwick United Kingdom says:

      Are you kidding Karl, this is quite clearly a new technology, no secret there. I'm surprised at your attempt to put this down, perhapse you're connected to a company making money out of over priced glucose testing strips and meters?
      In my view this technology is a good example of much needed research and may improve my and millions of other people affected by this condition.
      This is a good example of your so called venture capital as an investment, not waste.
      In short, who are you trying to kid!

  2. Sinead sinead Sinead sinead Ireland says:

    Blood sugar fluctuates with different meals, not sure I constantly need to know that my blood sugar has risen after every meal. This device seems suitable for people for people suffering a lot of hypos or a loss of hypo awareness. It may however be an advantage to monitor how different foods can affect blood sugar fluctuations, by this I mean high fat versus low fat, proteins and different types of carbs. It will obviously be somewhat beneficial. As for not having to prick my finger, this never bothered me as I have to inject insulin any way. I'd prefer if someone would come up with a feasible  non invasive method of insulin administration, or even a cure. But why invest money in discovering a cure, when there is more money to be made treating it.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Understanding the link between high-fat diets, insulin resistance, and diabetic heart disease